Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Dawn Svoronos Biography and Net Worth

Director of Xenon Pharmaceuticals

Ms. Svoronos has served as our Lead Independent Director since June 2021 and as a member of our Board since September 2016. Ms. Svoronos sits on the board of directors of the following publicly traded biopharmaceutical companies: Acelyrin Inc., Adverum Biotechnologies, Inc. and Theratechnologies Inc., where she is currently the Chair of its board of directors. Ms. Svoronos retired in 2011 from Merck & Co., Inc. following a 23-year career in commercial positions of increasing seniority, most recently as President of Europe and Canada. Her previously held positions with Merck include Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos previously sat on the boards of PTC Therapeutics, Inc., Global Blood Therapeutics, Inc., Endocyte, Inc., and Medivation Inc. Ms. Svoronos received a B.A. in English and French Literature from Carleton University.

What is Dawn Svoronos' net worth?: The estimated net worth of Dawn Svoronos is at least $957,750.00 as of August 24th, 2023. Ms. Svoronos owns 25,000 shares of Xenon Pharmaceuticals stock worth more than $957,750 as of November 18th. This net worth approximation does not reflect any other investments that Ms. Svoronos may own. Learn More about Dawn Svoronos' net worth.
How do I contact Dawn Svoronos?: The corporate mailing address for Ms. Svoronos and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Dawn Svoronos' contact information.
Has Dawn Svoronos been buying or selling shares of Xenon Pharmaceuticals?: Dawn Svoronos has not been actively trading shares of Xenon Pharmaceuticals over the course of the past ninety days. Most recently, Dawn Svoronos sold 25,000 shares of the business's stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $38.70, for a transaction totalling $967,500.00. Following the completion of the sale, the director now directly owns 25,000 shares of the company's stock, valued at $967,500. Learn More on Dawn Svoronos' trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 31,517 shares worth more than $1,379,060.56. The most recent insider tranaction occured on March, 7th when EVP Sherrington Robin sold 7,137 shares worth more than $330,300.36. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 3/7/2024.

Dawn Svoronos Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/24/2023	Sell	25,000	$38.70	$967,500.00	25,000

Dawn Svoronos Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $38.31

$37.38

$40.01

50 Day Range

MA: $41.21

$38.06

$45.74

2 Week Range

Now: $38.31

$28.20

$50.99

Volume

878,189 shs

Average Volume

389,378 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Get Your Free Gold Guide